In July, Exact Sciences’ chairman and CEO Kevin Conroy presented a proposal to crosswalk Cologuard from its current G-code to a CPT code.
The panel’s recent meeting was to determine if the colorectal cancer screening test would maintain its $492.72 reimbursement after crosswalking the code.
The advisory panel unanimously voted to maintain Cologuard’s current pricing. The vote was 11 to 0, with one abstention.
“CMS will post a preliminary determination after considering the July meeting comments, today’s panel vote and other written comments. A final determination is expected to be released in the November timeframe and will be effective Jan. 1, 2016,” said Mr. Conroy.
More articles on gastroenterology:
4 GI physicians in the news – Aug. 21, 2015
FDA clears new dietary supplements: 3 points
Memorial Hermann implements EndoSoft software for GI
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.